The Cancer Letter

Inside information on cancer research and drug development

In Brief

Gulley named VP of SITC; Luke, Bruno, Warren named at-large directors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

James L. Gulley was elected vice president of The Society for Immunotherapy of Cancer. Gulley is co-director of the Center for Immuno-Oncology, the director of the Medical Oncology Service, and deputy director of the Center for Cancer Research at NCI. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

SITC-IBCG publishes bladder cancer clinical trial design recommendations

The Society for Immunotherapy of Cancer and the International Bladder Cancer Group published bladder cancer clinical trial design recommendations, which provide a detailed clinical trial design guide to maximize the chance of capturing the benefit of medical therapies for each unique stage of bladder cancer, from low-risk non-muscle invasive bladder cancer to metastatic disease.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account